PTC/SB/88s (38-03.)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		10750845			
	Filing Date		2004-01-05			
	First Named Inventor	Sung	-Chul KANG			
	Art Unit		1763			
	Examiner Name	John	S YCHU			
	Attorney Docket Number		PNK-0205			

				U.S.	PATENTS	Remove		
Examiner Initial*			Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Releva	ages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	6159656	US	2000-12-12	KAWABE, et al.			
	2	6265135	us	2001-07-24	KODAMA, et al.			
	3	6410204	us	2002-06-25	KODAMA, et al.			
If you wisi	h to a	dd additional U.S. Pater	t citatio	n information pl	ease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No Publication Number Kind Code <sup>1</sup>			Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20020058200	US	2002-05-26	FUJIMORI, et al.			
	2	20020009666	us	2002-01-24	SATO, et al.			
	3	20020051933	US	2002-05-02	KODAMA, et al.			
					I .			

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10750845
Filing Date		2004-01-05
First Named Inventor Sung-		Chul KANG
Art Unit		1763
Examiner Name John		S YCHU
Attornou Docket Number		DNIX 1905

	4	20020	0061464	US	2002-05	5-23	AOAI, et al.						
	5	20020	0102491	US	2002-08	3-01	KODAMA, et al.						
	6	20020	0155383	US	2002-10-24		FUJIMORI, et al.						
If you wis	h to a	dd add	fitional U.S. Publi	shed Ap	plication	n citatio	n information p	oleas	e click the Add	butto	n. Add		
					FOREIG	GN PAT	ENT DOCUM	ENT	s		Remove		
Examiner Initial*			Publication Date	Name of Patentee or Applicant of cited Document			Pages,Col where Reli Passages Figures Ap	evant or Relev	Te				
1 1020020079413 KR		KR			2002-10-19				w/English Abstract				
If you wis	h to a	dd add	fitional Foreign Pa	atent Do	cument	citation	information pl	ease	click the Add	buttor	Add		
				NON	I-PATE	NT LITE	RATURE DO	CUM	IENTS		Remove		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (took) (took, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, dity and/or country where published.								n <sub>T</sub> s				
	1												
If you wis	h to a	dd add	fitional non-paten	t literatu	ire docui	ment cit	ation informati	ion p	lease click the	Add b	outton Ad	id	
					EX	AMINE	R SIGNATUR	E					
Examiner	Examiner Signature Date Considered												

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number		10750845
Filing Date		2004-01-05
First Named Inventor	Sung	-Chul KANG
Art Unit		1763
Examiner Name	John	S YCHU
Attorney Docket Numb	er	PNK-0205
	Filing Date First Named Inventor Art Unit Examiner Name	Filing Date First Named Inventor Sung Art Unit

See Find Codes of USPTO Platfor Documents at view, USPTO, DOV or MFEP 901.04. \* Enter office that its seas the document, by the Involvator code (WIPO Standard ST 3). \* See Japanese patent documents, the indusion of the pagent of the injection result procedure the senial number of the patent document. \*
\*\*Individual Cocument by the appropriate symbols as indicated on the document under WIPO Standard ST 1,6 if possible. \*
\*\*Applicant is to place as check mark here if Empirical Insurance and the Cocument of the Applicant is to place a check mark here if Empirical Insurance and another and the Cocument of the Applicant is to place a check mark here if Empirical Insurance and another and the Cocument of the Applicant is to place a check mark here if Empirical Insurance and another and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here if Empirical Insurance and the Applicant is to place a check mark here in the Applicant is to place a check mark here. The Applicant is the Applicant

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10750845
Filing Date		2004-01-05
First Named Inventor	Sung	Chul KANG
Art Unit		1763
Examiner Name John		S YCHU
Attorney Docket Number		PNK-0205

#### CERTIFICATION STATEMENT

			selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97 CFF 1.97(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- \_ ....

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Dana A. Gronbeck/	Date (YYYY-MM-DD)	2007-05-17
Name/Print	Dana A. Gronbeck	Registration Number	55226

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.